SCHADE CHRISTIAN S

Form 4

September 03, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * SCHADE CHRISTIAN S

(First)

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

(Middle)

MEDAREX INC [MEDX] 3. Date of Earliest Transaction

Director 10% Owner

(Check all applicable)

MEDAREX, INC., 707 STATE

ROAD

(Last)

(Month/Day/Year)

X_ Officer (give title Other (specify

09/01/2009

below) SVP & CFO

(Street)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

(Instr. 4)

Person

PRINCETON, NJ 08540

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if

(Month/Day/Year)

3. Code

(Instr. 8)

4. Securities TransactionAcquired (A) or Disposed of (D)

Code V Amount (D) Price

(Instr. 3, 4 and 5)

(A)

5. Amount of Securities Beneficially Owned Following

Reported

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial Ownership (T)

(Instr. 4)

Transaction(s) (Instr. 3 and 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

Conversion or Exercise

3. Transaction Date 3A. Deemed (Month/Day/Year)

Execution Date, if any

4. 5. Number of **Transaction**Derivative Code Securities

6. Date Exercisable and **Expiration Date** (Month/Day/Year)

7. Title and Amount of **Underlying Securities** (Instr. 3 and 4)

Edgar Filing: SCHADE CHRISTIAN S - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Stock Option (right to buy)	\$ 9.9	09/01/2009		D	250,000	<u>(1)</u>	09/05/2015	Common Stock	250,00
Stock Option (right to buy)	\$ 7.16	09/01/2009		D	200,000	(2)	10/13/2013	Common Stock	200,00
Stock Option (right to buy)	\$ 5.61	09/01/2009		D	185,000	(3)	07/25/2014	Common Stock	185,00
Stock Option (right to buy)	\$ 14.89	09/01/2009		D	100,000	<u>(4)</u>	09/18/2011	Common Stock	100,00
Stock Option (right to buy)	\$ 9.07	09/01/2009		D	135,000	<u>(5)</u>	03/02/2018	Common Stock	135,00
Stock Option (right to buy)	\$ 8.11	09/01/2009		D	250,000	<u>(6)</u>	07/10/2012	Common Stock	250,00
Stock Option (right to buy)	\$ 6.33	09/01/2009		D	165,000	<u>(7)</u>	09/07/2013	Common Stock	165,00
Stock Option (right to buy)	\$ 3.72	09/01/2009		D	135,000	<u>(8)</u>	03/04/2019	Common Stock	135,00
Restricted Stock Units	<u>(9)</u>	09/01/2009		D	45,000	(10)	<u>(11)</u>	Common Stock	45,000
Restricted Stock Units	<u>(9)</u>	09/01/2009		D	45,000	(10)	(12)	Common Stock	45,000
	<u>(9)</u>	09/01/2009		D	9,182	(13)	(14)		9,182

Edgar Filing: SCHADE CHRISTIAN S - Form 4

Restricted Stock Units							Common Stock	
Restircted Stock Units	<u>(9)</u>	09/01/2009	D	11,262	(15)	(16)	Common Stock	11,262
Restricted Stock Units	<u>(9)</u>	09/01/2009	D	22,442	(17)	(18)	Common Stock	22,442

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		

SCHADE CHRISTIAN S MEDAREX, INC. 707 STATE ROAD PRINCETON, NJ 08540

SVP & CFO

Signatures

CHRISTIAN S.

SCHADE 09/03/2009

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This option was canceled in the merger in exchange for a cash payment of \$1,525,000.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- This option was canceled in the merger in exchange for a cash payment of \$1,768,999.90, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- This option was canceled in the merger in exchange for a cash payment of \$1,923,075.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- This option was canceled in the merger in exchange for a cash payment of \$111,000.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- This option was canceled in the merger in exchange for a cash payment of \$936,225.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- This option was canceled in the merger in exchange for a cash payment of \$1,972,500.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (7) This option was canceled in the merger in exchange for a cash payment of \$1,595,550.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and

Reporting Owners 3

Edgar Filing: SCHADE CHRISTIAN S - Form 4

Bristol-Myers Squibb.

- This option was canceled in the merger in exchange for a cash payment of \$1,657,800.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (9) Each Restricted Stock Unit represents a contingent right to receive one (1) share of Medarex, Inc. Common Stock.
- (10) This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of \$720,000.00, based on the merger consideration (\$16 per share) pursuant to the merger agreement between issuer and Bristol-Myers Squibb.
- (11) The receipt of these Restricted Stock Units was deferred until March 3, 2013.
- (12) The Restricted Stock Units vest ratably over four years beginning on April 5, 2010.
- (13) This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of \$146,912.00, based on the merger consideration (\$16 per share) pursuant to the merger agreement between issuer and Bristol-Myers Squibb.
- (14) The receipt of these Restricted Stock Units was deferred until February 24, 2014.
- (15) This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of \$180,192.00, based on the merger consideration (\$16 per share) pursuant to the merger agreement between issuer and Bristol-Myers Squibb.
- (16) The receipt of these Restricted Stock Units was deferred until March 1, 2012.
- (17) This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of \$359,072.00, based on the merger consideration (\$16 per share) pursuant to the merger agreement between issuer and Bristol-Myers Squibb.
- (18) The receipt of these Restricted Stock Units was deferred until March 13, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.